MedTrace Logo

Feasibility of FMISO in Brain Tumors

NCT03649880 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-03-25

No results posted yet for this study

Summary

This phase II trial studies how well ¹⁸F- fluoromisonidazole (FMISO) works with positron emission tomography (PET)/magnetic resonance imaging (MRI) in assessing participants with malignant (cancerous) brain tumors. FMISO provides information about the oxygen levels in a tumor, which may affect how the tumor behaves. PET/MRI imaging produces images of the brain and how the body functions. FMISO PET/MRI may help investigators see how much oxygen is getting in the brain tumors.

Conditions

  • Malignant Brain Neoplasm

Interventions

DRUG

¹⁸F-Fluoromisonidazole

Given IV

PROCEDURE

Computed Tomography

Undergo PET/CT

PROCEDURE

Magnetic Resonance Imaging

Undergo PET/MRI or PET/CT

PROCEDURE

Positron Emission Tomography

Undergo PET/MRI

PROCEDURE

Oxygen Therapy

Receive supplemental oxygen

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Oregon Health and Science University

    collaborator OTHER

  • Weill Cornell University

    collaborator UNKNOWN

  • OHSU Knight Cancer Institute

    lead OTHER

Principal Investigators

  • Ramon Barajas · OHSU Knight Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-01
Primary Completion
2029-01-31
Completion
2030-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03649880 on ClinicalTrials.gov